Company Product Description Indication Status
Phase I
Altasciences Co. Inc., of Laval, Quebec, and Roivant Sciences Ltd., of New York Gimsilumab Fully human monoclonal antibody targeting GM-CSF SARS-CoV-2 patients at risk of developing acute respiratory distress syndrome Completed study; Roivant said it will prioritize trials in patients with COVID-19
Arbutus Biopharma Corp., of Warminster, Pa. AB-729 RNA interference therapeutic targeted to hepatocytes using covalently conjugated N-acetylgalactosamine delivery technology Hepatitis B Dosing at either 60 mg or 180 mg was generally safe and well-tolerated and resulted in meaningful reductions in HBsAg levels
Translate Bio Inc., of Lexington, Mass. MRT-5005 Inhaled mRNA therapeutic Cystic fibrosis Company anticipates related interruptions in enrollment, dosing and follow-up due to COVID-19

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments